• Donate
  • Contact
Canadian Association of Pompe
  • Home
  • About Us
    • Personal Stories
    • Newsletter
  • About Pompe
  • Blog
  • Links
  • Connections
Select Page
Amicus Therapeutics Receives Breakthrough Therapy Designation for Pompe Treatment

Amicus Therapeutics Receives Breakthrough Therapy Designation for Pompe Treatment

by Brad Crittenden | Feb 25, 2019 | News

Amicus Therapeutics announced today that they have received Breakthrough Therapy Designation (BTD) for their AT-GAA treatment for Pompe disease.

Recent Posts

  • Audentes Therapeutics Update on Pompe and Other Programs
  • 2019 CAP Annual General Meeting
  • Amicus Therapeutics Presents Positive Preclinical Pompe Disease Gene Therapy Data
  • April 15, A Day of Reflection
  • International Pompe Day – Moving On with Pompe!
  • Terms
  • Privacy

Copyright © 2006 - 2019 Canadian Association of Pompe | Developed by PacificByte

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok